ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Esmeron®:MSD Merck Sharp & Dohme AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
M03AC09 - Rocuronium BromideATC-DDD Version 2016. Source: WHO
M - Musculo-Skeletal System
 
M03 - Muscle Relaxants

This group comprises peripherally, centrally and directly acting muscle relaxants.
See also G04BD - Drugs for urinary frequency and incontinence.

M03A - Muscle Relaxants, Peripherally Acting Agents

This group comprises peripherally acting muscle relaxants such as curare alkaloids and suxamethonium.
The drugs in this group are mainly used together with anesthetics.

As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.

M03AC - Other Quaternary Ammonium Compounds

Sugammadex indicated for reversal of neuromuscular blockade induced by rocuronium or vecuronium is classified in V03AB - Antidotes.

M03AC09 - Rocuronium Bromide
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home